Addex Therapeutics (Addex Therapeutics) Debt-to-Equity : 0.30 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Addex Therapeutics Debt-to-Equity?

Addex Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.32 Mil. Addex Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.08 Mil. Addex Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1.32 Mil. Addex Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Addex Therapeutics's Debt-to-Equity or its related term are showing as below:

ADXN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.3
Current: 0.3

During the past 13 years, the highest Debt-to-Equity Ratio of Addex Therapeutics was 0.30. The lowest was 0.02. And the median was 0.04.

ADXN's Debt-to-Equity is ranked worse than
65.26% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs ADXN: 0.30

Addex Therapeutics Debt-to-Equity Historical Data

The historical data trend for Addex Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Debt-to-Equity Chart

Addex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.04

0.03

0.08

0.30

Addex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.06	0.04	0.08	0.30

Competitive Comparison of Addex Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Addex Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Debt-to-Equity falls into.

Addex Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Addex Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	0.081)	/	1.324
	=	0.30

Addex Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	0.081)	/	1.324
	=	0.30

Addex Therapeutics (NAS:ADXN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Addex Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Addex Therapeutics (Addex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (NAS:ADXN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ADXNz:UK APE1:Germany ADXN:Switzerland

Address

Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202

Website

https://www.addextherapeutics.com

Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (Addex Therapeutics) Headlines

From GuruFocus

Thinking about buying stock in Applovin, Sonos, WiMi Hologram Cloud, Addex Therapeutics, or Snap?

By PRNewswire PRNewswire • 02-09-2023

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire • 02-24-2021